StreetInsider.com News Articles

AlphaGen Clarifies Matters to be Considered at Annual General and Special Meeting

Mon, 15 Jun 2026 17:00:00 -0400

VANCOUVER, British Columbia, June 15, 2026 (GLOBE NEWSWIRE) -- AlphaGen Intelligence Corp. (CSE: AIC | OTC: APETF | FSE: G4G) ("AlphaGen" or the "Company") wishes to clarify certain matters relating to its Annual General and Special Meeting of Shareholders (the "Meeting") scheduled to be held on June 19, 2026.

The Company confirms that the ordinary resolution relating to the approval of the share purchase agreement dated March 31, 2026 among the Company, Quantum Vision Holdings Inc. ("Quantum") and the shareholders of Quantum, and the transactions contemplated thereby (the "Transaction"), will not be presented for consideration at the

AlphaGen Clarifies Matters to be Considered at Annual General and Special Meeting

Mon, 15 Jun 2026 17:00:00 -0400

AlphaGen Clarifies Matters to be Considered at Annual General and Special Meeting

Mon, 15 Jun 2026 17:00:00 -0400

AlphaGen Clarifies Matters to be Considered at Annual General and Special Meeting

Mon, 15 Jun 2026 17:00:00 -0400

AlphaGen Clarifies Matters to be Considered at Annual General and Special Meeting

Mon, 15 Jun 2026 17:00:00 -0400

AlphaGen Clarifies Matters to be Considered at Annual General and Special Meeting

Mon, 15 Jun 2026 17:00:00 -0400

AlphaGen Clarifies Matters to be Considered at Annual General and Special Meeting

Mon, 15 Jun 2026 17:00:00 -0400

AlphaGen Clarifies Matters to be Considered at Annual General and Special Meeting

Mon, 15 Jun 2026 17:00:00 -0400

AlphaGen to acquire Quantum Vision in $9.8 million share exchange deal

Tue, 31 Mar 2026 08:01:54 -0400

AlphaGen Intelligence Corp (CSE: AIC) (FSE: G4G) announced it signed a definitive agreement to acquire all outstanding shares of Quantum Vision Holdings Inc. through a share exchange transaction valued at $9.8 million.

Under the agreement, AlphaGen will issue 24.5 million common shares in exchange for all Quantum Vision shares on a one-to-one basis, with each AlphaGen share valued at $0.40. The transaction is expected to complete by July 31, 2026, subject to various conditions including Canadian Securities Exchange approval and shareholder consent.

Trading in AlphaGen shares remains halted on the CSE until required documentation is filed and accepted by the exchange. The

AlphaGen to acquire Quantum Vision in $9.8 million share exchange deal

Tue, 31 Mar 2026 08:01:54 -0400

Trading in AlphaGen shares remains halted on the CSE until required documentation is filed and accepted by the exchange. The

AlphaGen to acquire Quantum Vision in $9.8 million share exchange deal

Tue, 31 Mar 2026 08:01:54 -0400

Trading in AlphaGen shares remains halted on the CSE until required documentation is filed and accepted by the exchange. The

AlphaGen to acquire Quantum Vision in $9.8 million share exchange deal

Tue, 31 Mar 2026 08:01:54 -0400

Trading in AlphaGen shares remains halted on the CSE until required documentation is filed and accepted by the exchange. The

AlphaGen to acquire Quantum Vision in $9.8 million share exchange deal

Tue, 31 Mar 2026 08:01:54 -0400

Trading in AlphaGen shares remains halted on the CSE until required documentation is filed and accepted by the exchange. The

AlphaGen to acquire Quantum Vision in $9.8 million share exchange deal

Tue, 31 Mar 2026 08:01:54 -0400

Trading in AlphaGen shares remains halted on the CSE until required documentation is filed and accepted by the exchange. The

AlphaGen Announces Definitive Agreement to Acquire Quantum Vision Holdings Inc.

Tue, 31 Mar 2026 08:00:00 -0400

VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- AlphaGen Intelligence Corp. (CSE: AIC) (FSE: G4G) ("AlphaGen" or, the “Company”) is pleased to announce that it has entered into a definitive share exchange agreement (the "Agreement") with Quantum Vision Holdings Inc. ("Quantum Vision") pursuant to which AlphaGen will acquire all of the issued and outstanding shares of Quantum Vision (the "Transaction"). The Transaction will constitute a "Fundamental Change" of AlphaGen under the policies of the Canadian Securities Exchange (the "CSE").